National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.

Rapid Review Process Complete
Rapid review received 04/09/2017
Rapid review completed 19/09/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by the HSE 25/09/2017
Pre-submission consultation with applicant 23/10/2017
Submission received from applicant 07/02/2018
Preliminary review part I sent to applicant 25/04/2018
Preliminary review part II sent to applicant 23/05/2018
Applicant response to preliminary review part I 25/05/2018
Applicant response to preliminary review part II 14/06/2018
NCPE assessment re-commenced 15/06/2018
Current status NCPE Assessment ongoing